B
VIRX

Bailard’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bailard’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,899
Closed -$12.4K – 825
2023
Q3 		$12.4K Sell
11,899
-35,801
-75% -$48.6K ﹤0.01% 694
2023
Q2 		$67.3K Buy
47,700
+27,800
+140% +$39.8K ﹤0.01% 674
2023
Q1 		$31.6K Buy
+19,900
New +$36.2K ﹤0.01% 709
2021
Q4 		– Sell
-50,000
Closed -$401K – 800
2021
Q3 		$401K Sell
50,000
-95,000
-66% -$936K 0.01% 451
2021
Q2 		$1.64M Buy
145,000
+108,000
+292% +$1.08M 0.06% 224
2021
Q1 		$342K Buy
+37,000
New +$386K 0.01% 474

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's VIRX Position: Q4 2023 in Review

Bailard sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2023, closing a stake of 11,899 shares — an estimated $12.4K sold.

Bailard first reported a position in VIRX in Q1 2021 and held it in 6 quarters. The position peaked at $1.64M in Q2 2021. 42 funds tracked by Wall St. Rank hold VIRX as of Q4 2023.

  • Bailard reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Bailard sold 11,899 Viracta Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $12.4K.
  • Bailard first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • Bailard's Viracta Therapeutics, Inc. Common Stock position peaked at $1.64M in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Bailard's 13F filing for Q4 2023, filed 2 Feb 2024.